CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade
Rhea-AI Filing Summary
CNS Pharmaceuticals, Inc. director Michal Fisher reported an open-market purchase of company stock. On May 18, 2026, Fisher purchased 2,000 shares of CNSP common stock at $5.00 per share. Following this transaction, Fisher directly holds 2,000 common shares of the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,000 shares
Net Buy
1 txn
Insider
Fisher Michal
Role
Director
Bought
2,000 shs ($10K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,000 | $5.00 | $10K |
Holdings After Transaction:
Common Stock — 2,000 shares (Direct)
Key Figures
Shares purchased: 2,000 shares
Purchase price: $5.00 per share
Shares owned after transaction: 2,000 shares
+1 more
4 metrics
Shares purchased
2,000 shares
Common Stock purchased on May 18, 2026
Purchase price
$5.00 per share
Price for the May 18, 2026 common stock purchase
Shares owned after transaction
2,000 shares
Total direct holdings following the reported purchase
Net buy shares
2,000 shares
Net buy volume across all transactions in this Form 4
Key Terms
open market, private transaction, Rule 10b5-1
3 terms
open market financial
"Purchase in open market or private transaction"
An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.
private transaction financial
"Purchase in open market or private transaction"
A private transaction is the sale or transfer of securities, assets, or ownership stakes carried out directly between a small number of parties rather than on a public exchange. For investors it matters because these deals are less visible and often less liquid than public trades, so pricing can be harder to verify, the investment can be harder to sell quickly, and buyers or sellers may gain strategic advantages not available in open markets — like negotiated terms similar to a private garage sale versus a crowded marketplace.
Rule 10b5-1 regulatory
"Rule 10b5-1 checkbox is not checked (aff_10b5_one: false)"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transaction did CNSP director Michal Fisher report?
Director Michal Fisher reported purchasing 2,000 shares of CNS Pharmaceuticals, Inc. (CNSP) common stock. The transaction occurred on May 18, 2026 and was reported as an open-market or private purchase at $5.00 per share.
Was the CNSP insider trade by Michal Fisher a purchase or a sale?
The transaction reported by Michal Fisher was a purchase of CNSP common stock. The Form 4 shows a buy of 2,000 shares at $5.00 per share on May 18, 2026, with no sales reported in this filing.
Did the CNSP Form 4 indicate trades under a Rule 10b5-1 plan?
No. The Form 4’s Rule 10b5-1 checkbox is not checked, indicating the reported transaction was not affirmed as made under a Rule 10b5-1 trading plan. The filing instead classifies it as a standard open-market or private purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
